Brief: Shield Therapeutics Announces Approval For ACCRUFeR In China Expected In Q1 2026
30/01/2026 07:20
Jan 30 (Reuters) - Shield Therapeutics PLC STXS.L: SHIELD THERAPEUTICS - APPROVAL FOR ACCRUFER IN CHINA EXPECTED IN Q1 2026 SHIELD THERAPEUTICS - APPROVAL FOR ACCRUFER IN CHINA EXPECTED IN Q1 2026 SHIELD THERAPEUTICS PLC - CHINA LICENSE AGREEMENT INCLUDES $7.9M MILESTONE TO SHIELD SHIELD THERAPEUTICS PLC - TO TERMINATE AOP AGREEMENT USING ASK MILESTONE PAYMENT Source text: ID:nRSd0029Ra Further company coverage: STXS.L ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Shield Therapeutics
See all newsBrief: Shield Therapeutics To Assume Full Commercial Control Of ACCRUFeR In US
Shield Therapeutics - Shield assumes full control of ACCRUFeR® in the US
Shield Therapeutics - Interim results for the six months ended 30 Jun 26
Brief: Shield Therapeutics Says On Track For Profitability In 2026; Appoints Michael Jensen As CFO
Shield Therapeutics - Q2 and H1 2026 Trading Update